VX-936
Phase 2
Vertex PharmaceuticalsVX-936 is one of 41 therapeutic programs targeting Hepatitis C. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
306 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Zepatier
Merck & Co.Phase 3
Peginterferon Alfa-2
RochePhase 3
Lexapro
AbbViePhase 3
Victrelis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Pegylated Interferon
Merck & Co.Phase 3
TMC435
Johnson & JohnsonPhase 3
Zetia
OOrganon and Co
Phase 3
Ombitasvir/paritaprevir/ritonavir
AbbViePhase 3
Peg-Interferon Alfa-2a
Bristol-Myers SquibbPhase 3
Thymalfasin
SSciClone Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for VX-936. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company